489.31
-5.38(-1.09%)
Currency In USD
| Previous Close | 494.69 |
| Open | 489.75 |
| Day High | 497.54 |
| Day Low | 480.02 |
| 52-Week High | 615 |
| 52-Week Low | 265 |
| Volume | 668,552 |
| Average Volume | 358,634 |
| Market Cap | 11.11B |
| PE | -38.32 |
| EPS | -12.77 |
| Moving Average 50 Days | 551.9 |
| Moving Average 200 Days | 411.02 |
| Change | -5.38 |
If you invested $1000 in Madrigal Pharmaceuticals, Inc. (MDGL) 10 years ago, it would be worth $60,783.85 as of February 01, 2026 at a share price of $489.31. Whereas If you bought $1000 worth of Madrigal Pharmaceuticals, Inc. (MDGL) shares 5 years ago, it would be worth $4,218.55 as of February 01, 2026 at a share price of $489.31.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jan 21, 2026 9:05 PM GMT
CONSHOHOCKEN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced tha
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor
GlobeNewswire Inc.
Jan 09, 2026 1:00 PM GMT
Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for potential additive therapeutic benefit in MASHMadrigal
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 15, 2025 9:05 PM GMT
CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on Monday, January 12, 2026 at 1:30pm PST. The pres